Understanding how specific RNA readers affect the immune system's response to radiation and immunotherapy for cancer
Elucidating the Roles of RNA m6A readers Y1 and Y2 in radiation-induced immunity and immunotherapy
['FUNDING_R01'] · UNIVERSITY OF CHICAGO · NIH-11105831
This project explores how certain RNA molecules influence the immune system's fight against cancer when treated with radiation and immunotherapy.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF CHICAGO (nih funded) |
| Locations | 1 site (CHICAGO, UNITED STATES) |
| Trial ID | NIH-11105831 on ClinicalTrials.gov |
What this research studies
This research aims to improve cancer treatment by understanding why some patients do not fully benefit from combined radiation and immunotherapy. We are looking closely at specific changes in RNA molecules, called m6A readers, to see how they affect immune cells within tumors after radiation. By uncovering these molecular details, we hope to find new ways to make cancer immunotherapies more effective for a broader range of people. This work could ultimately lead to better treatment outcomes for patients battling cancer.
Who could benefit from this research
Good fit: Patients with various types of cancer who are undergoing or considering radiation and immunotherapy might eventually benefit from this research.
Not a fit: Patients whose cancer does not involve the specific RNA pathways or immune responses being studied may not directly benefit from this particular line of research.
Why it matters
Potential benefit: If successful, this work could lead to new strategies to make radiation and immunotherapy more effective for a wider range of cancer patients.
How similar studies have performed: While combined radiation and immunotherapy has shown some success, this project uses novel techniques in RNA modification, which are largely untested in this specific context.
Where this research is happening
CHICAGO, UNITED STATES
- UNIVERSITY OF CHICAGO — CHICAGO, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: WEICHSELBAUM, RALPH R — UNIVERSITY OF CHICAGO
- Study coordinator: WEICHSELBAUM, RALPH R
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Cancer Treatment, Cancers